AC Immune SA reported that ACI-7104 produced a 100% antibody response after three immunizations in Part 1 of the VacSYn Phase 2 trial through week-100. The findings support continued Part 1 work, FDA discussions planned for early 2027 and an expanded Phase 2 intended to provide the basis for a Phase 3 decision.
Key Highlights
- ACI-7104 produced antibody penetration into cerebrospinal fluid in all patients.
- Exploratory analysis found a signal for total alpha-synuclein in cerebrospinal fluid.
- The VacSYn program is continuing through a 2-year extension while Part 2 advances.
All primary endpoints were met, and the treatment was generally safe and well tolerated. The data also showed a 100% response rate after three immunizations, supporting the program’s move toward its next development stage. The trial is randomized, double-blind and placebo-controlled.
ACI-7104 Meets Part 1 Endpoints
Part 1 included 34 patients, with 25 assigned to ACI-7104 and nine to placebo. The allocation followed a 3:1 randomization design, and the results covered all participants after 100 weeks since treatment began. AC Immune (NASDAQ: ACIU) said each of those measures was met, with ACI-7104 showing a generally favorable safety and tolerability profile through week-100. The treatment generated antibodies against the immunizing alpha-synuclein target antigen PD01 in every patient after three immunizations. Antibody reactivity against aggregated forms of alpha-synuclein was also observed.
Antibodies Reach Cerebrospinal Fluid
Antibody penetration into cerebrospinal fluid was observed across all patients. The company also identified a signal involving total alpha-synuclein in cerebrospinal fluid, which it said provided preliminary evidence consistent with target engagement. Part 1 was not designed to assess biomarker or clinical outcomes. Exploratory work nevertheless monitored selected cerebrospinal-fluid biomarkers, including total alpha-synuclein and Neurofilament Light chain, alongside clinical measures of disease activity. Additional exploratory correlation analyses found trends indicating an association between antibody levels and disease-activity measures. AC Immune said the observations provide a basis for further investigation, while also describing the Part 1 sample size as limited.
FDA Path Planned For 2027
VacSYn will continue in Part 1 through a 2-year extension as the program advances toward Part 2. AC Immune is consolidating the final Part 2 design for submission to the FDA. Discussions with the FDA about the future development path are planned for early 2027.



Please wait processing your request...